MilliporeSigma
All Photos(1)

Documents

P2371

Sigma-Aldrich

Pamidronate disodium salt hydrate

≥95% (NMR), solid

Sign Into View Organizational & Contract Pricing

Synonym(s):
3-Amino-1-hydroxy-1-phosphonopropanephosphonic acid disodium salt hydrate
Empirical Formula (Hill Notation):
C3H9NO7P2Na2 · xH2O
CAS Number:
Molecular Weight:
279.03 (anhydrous basis)
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥95% (NMR)

form

solid

color

white

mp

300 °C

solubility

H2O: 28 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O

InChI

1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2

InChI key

TVQNUQCYOOJTMK-UHFFFAOYSA-L

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
P0039506600P5248
form

solid

form

solid

form

solid

form

solid

color

white

color

red

color

white

color

white

solubility

H2O: 28 mg/mL

solubility

DMSO: 10 mg/mL, clear (warmed)

solubility

water: 10 mg/mL

solubility

H2O: ≥10 mg/mL

originator

Novartis

originator

-

originator

-

originator

-

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

2-8°C

Biochem/physiol Actions

Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.
Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Customers Also Viewed

Slide 1 of 10

1 of 10

Alendronate sodium United States Pharmacopeia (USP) Reference Standard

USP

1012780

Alendronate sodium

Sodium alendronate trihydrate European Pharmacopoeia (EP) Reference Standard

Y0001727

Sodium alendronate trihydrate

Sigma-Aldrich

Sigma-Aldrich

SML0650

Risedronate sodium

SR 12813 ≥98%, solid

Sigma-Aldrich

S4194

SR 12813

6-Fluoromevalonate ≥90% (GC), viscous liquid

Sigma-Aldrich

F2929

6-Fluoromevalonate

C10 bisphosphonate Avanti Polar Lipids 860480P, powder

Avanti

860480P

C10 bisphosphonate

Sodium alendronate British Pharmacopoeia (BP) Reference Standard

BP830

Sodium alendronate

George Bullock et al.
Materials (Basel, Switzerland), 13(9) (2020-05-07)
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of bisphosphonate therapy, characterised by exposed necrotic bone. The soft tissues of the oral mucosa no longer provide a protective barrier and MRONJ patients experience pain, infections and difficulties eating.
Yan Wang et al.
PloS one, 7(9), e44868-e44868 (2012-10-03)
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease. This lack of clarity primarily stems from the lack of sufficient
Raimund Hirschberg
Current opinion in supportive and palliative care, 6(3), 342-347 (2012-06-20)
More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases is associated with renal complications. The nature of renal injury from bisphosphonates has become clearer in recent years. Pamidronate can rarely cause (collapsing) focal segmental
Evangelos Terpos et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(18), 2347-2357 (2013-05-22)
The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published
Coralie Leblicq et al.
Pediatric blood & cancer, 60(5), 741-747 (2012-09-25)
Osteonecrosis (ON) is a severe complication of acute lymphoblastic leukemia (ALL) treatments. Recent studies suggest that bisphosphonates might reduce pain and loss of motor function in patients with ON. We assessed the effects of pamidronate compared to standard care in

Articles

Cyclic nucleotides, including cyclic AMP (cAMP), cyclic GMP (cGMP) and cyclic ADP-ribose, have been extensively studied as second messengers of intracellular events initiated by activation of GPCRs. cAMP modifies cell function in all eukaryotic cells, principally through the activation of cAMP-dependent protein kinase (PKA), but also through cAMP-gated ion channels and guanine nucleotide exchange factors directly activated by cAMP.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service